Lamotrigine Add-On for Depersonalization: Is the Titration Worth It?
A married chemistry teacher with three years of stable anxiety control still carries the depersonalization that triggered it. The disagreement isn't whether lamotrigine augmentation could help — it's whether a slow, rash-risk titration is worth it for someone already functioning well.
A music festival in his mid-twenties, one dose of MDMA, and a panic reaction that did not resolve the way panic reactions resolve. Instead of fading over hours it left behind a persistent sense that the world had gone slightly unreal — colors and sounds arriving a beat detached from where they should land. That single acute episode never closed. J.K. is 34 now, and twelve years on the depersonalization and derealization are chronic, low-grade most days, worse under stress.
He has taught chemistry for eleven years at the school where his wife also teaches; they have been married nine years and split the morning school run for their two kids most days without much discussion of who is doing what. He coaches the robotics club on Thursday afternoons. What none of that shows is the part he reports directly: specific recurring moments in his teaching day — handing back a graded exam, starting a new unit — where he has to consciously reground himself before he can continue. He has no other substance history and has never used MDMA again. Three years ago, once his anxiety about the unresolved symptoms had become a separate diagnosable problem in its own right, his psychiatrist started sertraline 150mg daily. The anxiety response was durable and real. The depersonalization did not move at all.
That split is informative rather than surprising. The two symptom clusters arose from one episode but appear to run on at least partly separate circuitry, which is why lamotrigine has been studied in this condition specifically as an add-on rather than a replacement. Sierra and colleagues' 2006 retrospective series of 32 patients found that 56% achieved at least a 30% reduction in Cambridge Depersonalization Scale score on lamotrigine — and among the subgroup taking it alongside an SSRI, as J.K. would be, 81.8% did, with improvement occurring at doses of 200 to 250 mg daily. Sierra's earlier placebo-controlled crossover trial of lamotrigine as a sole agent, by contrast, was negative. The mechanism — voltage-gated sodium channel blockade and reduced glutamate release — is a genuinely different lever from sertraline's serotonergic action rather than more of the same one. What it costs to pull that lever is a mandatory multi-week titration and a rare but serious rash risk, in a man whose outward life gives no sign that anything is wrong at all.
Adding a second lever
His sertraline has done what it's going to do for the depersonalization — three years is long enough to call that plateau real. Sierra's 2006 series of 32 patients is specific on this point: 56% overall reached a 30% or greater drop in Cambridge Depersonalization Scale score, and in the subgroup taking lamotrigine with an SSRI — which is exactly what we'd be doing — it was 81.8%. His earlier placebo-controlled crossover trial of lamotrigine alone found nothing. Voltage-gated sodium channel blockade is a genuinely different mechanism from serotonergic reuptake inhibition — not more of the same lever, a second one.
I don't dispute that the add-on rationale is real. But 81.8% is a response rate drawn from eleven patients inside a retrospective chart review, not a randomized trial, and Sierra's responders improved at 200 to 250 mg — the far end of the titration, not the near end. What we're asking him to take on is the full mandatory multi-week slow titration with a real, if rare, risk of a serious rash — a burden that's easy to understate when the patient in front of you is married, working full-time, and coaching a robotics club. That's a meaningful cost for a modest-effect-size adjunct in someone who is, by every outward measure, already doing well.
"Every outward measure" is exactly the problem with that framing — functioning well outwardly doesn't mean this costs him nothing. He's told us directly that he has specific, recurring moments in his own classroom where he has to consciously reground himself before he can keep teaching. That's not nothing just because it doesn't show up on a productivity metric.
The titration risk is real, but he has a three-year record of careful, consistent adherence with zero missed refills — exactly the patient profile who can execute a demanding schedule safely. I'd proceed with the standard slow titration, explicit written rash-education with same-day stop instructions, and a scheduled check-in at each dose increase rather than leaving it to him to notice something and call.
Agreed: begin lamotrigine as an SSRI add-on at 25mg every other day, following the standard slow titration schedule toward a target dose, with written rash-education, explicit same-day stop instructions for any new rash, and a scheduled check-in call at every dose increase rather than an open-ended "call if something comes up" arrangement.
The pharmacologist's caution about the titration burden was heard directly rather than argued past — the plan that resulted (scheduled check-ins, written stop instructions) exists specifically because that caution was taken seriously, not because it was overruled. All three left in agreement about both the plan and the reasoning behind it, which is a real, if narrower, resolution than simply outvoting the most cautious voice in the room.